Michaela B Kirschner

List of Publications by Year in Descending Order

39 papers	1,970 citations	18 h-index	44 g-index
49 ext. papers	2,264 ext. citations	5.2 avg, IF	4.55 L-index

#	Paper	IF	Citations
39	Surgical management of lung cancer during the COVID-19 pandemic - a narrative review and single-centre report.. *Swiss Medical Weekly*, **2022**, 152, w30109	3.1	0
38	Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. *Frontiers in Oncology*, **2021**, 11, 660039	5.3	5
37	Alterations in Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. *Clinical Cancer Research*, **2021**, 27, 2277-2291	12.9	2
36	Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma. *Cancers*, **2020**, 12,	6.6	1
35	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. *Frontiers in Endocrinology*, **2019**, 10, 89	5.7	4
34	Molecular Research in Chronic Thromboembolic Pulmonary Hypertension. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	13
33	miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. *Non-coding RNA*, **2019**, 5,	7.1	5
32	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. *Oncotarget*, **2019**, 10, 4125-4138	3.3	8
31	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2018**, 13, 258-272	8.9	29
30	FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. *Carcinogenesis*, **2018**, 39, 534-545	4.6	18
29	A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. *Molecular Oncology*, **2018**, 12, 58-73	7.9	18
28	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. *Npj Systems Biology and Applications*, **2018**, 4, 20	5	33
27	OA02.01 The microRNA-15/16 Family Regulates Tumor Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2017**, 12, S246	8.9	2
26	OA22.06 Refinement of the Prognostic miR-Score for Use in Diagnostic Specimens from Chemo-Naïve Malignant Pleural Mesothelioma Patients. *Journal of Thoracic Oncology*, **2017**, 12, S332	8.9	2
25	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2017**, 12, 1421-1433	8.9	97
24	Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. *Frontiers in Genetics*, **2017**, 8, 70	4.5	5
23	KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. *Molecular Cancer*, **2016**, 15, 44	42.1	36

22	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. *European Journal of Cancer*, **2016**, 63, 64-73	7.5	17
21	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. *British Journal of Cancer*, **2016**, 114, 524-31	8.7	15
20	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. *Genomics Data*, **2016**, 9, 44-9		4
19	MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. *Molecular Oncology*, **2015**, 9, 715-26	7.9	54
18	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. *Molecular Cancer Research*, **2015**, 13, 1106-18	6.6	38
17	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. *British Journal of Cancer*, **2015**, 113, 963-9	8.7	48
16	Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. *PLoS Genetics*, **2015**, 11, e1005633	6	64
15	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy **2015**,		14
14	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. *Oncotarget*, **2015**, 6, 23480-95	3.3	68
13	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. *British Journal of Cancer*, **2014**, 110, 510-9	8.7	37
12	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM).. *Journal of Clinical Oncology*, **2014**, 32, 7580-7580	2.2	
11	Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma.. *Journal of Clinical Oncology*, **2014**, 32, e18543-e18543	2.2	
10	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. *Annals of Oncology*, **2013**, 24, 3128-35	10.3	167
9	Does miR-1 play a role in malignant pleural mesothelioma development and progression?. *Chest*, **2013**, 144, 1971	5.3	
8	ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. *Journal of Thoracic Oncology*, **2013**, 8, 1317-28	8.9	25
7	Cell-free microRNAs: potential biomarkers in need of standardized reporting. *Frontiers in Genetics*, **2013**, 4, 56	4.5	53
6	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. *Frontiers in Genetics*, **2013**, 4, 94	4.5	211
5	Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). *PLoS ONE*, **2013**, 8, e70940	3.7	28

4	A novel microRNA-based treatment approach for malignant pleural mesothelioma.. *Journal of Clinical Oncology*, **2013**, 31, 7586-7586	2.2	
3	Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. *Journal of Thoracic Oncology*, **2012**, 7, 1184-91	8.9	95
2	Haemolysis during sample preparation alters microRNA content of plasma. *PLoS ONE*, **2011**, 6, e24145	3.7	380
1	Circulating microRNAs: Association with disease and potential use as biomarkers. *Critical Reviews in Oncology/Hematology*, **2011**, 80, 193-208	7	372